Ardelyx (NASDAQ: ARDX)
Ardelyx Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Ardelyx Company Info
Ardelyx, Inc. is a biopharmaceutical company. It engages in the research, development, and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Waltham, MA.
News & Analysis
Ardelyx Surpasses Q3 Revenue Estimates
The biopharma company reported strong revenue growth and a small net loss in Q3, surpassing analysts' expectations.
Why Ardelyx Stock Soared Today
Ardelyx delivered a strong quarter thanks to solid demand for its first FDA-approved product. Here's what investors need to know.
Why Ardelyx Stock Popped Today
Ardelyx finally received the long-awaited FDA approval for its chronic kidney disease drug.
Why Shares of Ardelyx Were Down Wednesday
The company's hopes for approval of a drug to treat chronic kidney disease took a hit.
2 Biotech Stocks That Can Rocket Higher in 2023, According to Wall Street
Recent analyst upgrades suggest these stocks can triple your money or better.
Why Ardelyx Stock Is Getting Crushed Today
The FDA doesn't appear to be impressed by the biotech's experimental kidney disease drug.
Why Ardelyx Stock Is Sinking Today
The FDA pushed back its approval decision for the company's lead candidate.
Why Ardelyx Stock Soared Today
The company's Japanese partner initiated pivotal late-stage studies of Ardelyx's lead candidate.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.